Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haematopoietic Stem Cell Therapy vs Natalizumab in Aggressive Relapsing-Remitting Multiple Sclerosis
2010-023560-40Phase 2Completed
- Sponsor
- Region Uppsala
- Start
- Dec 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of natalizumab in multiple sclerosis (MS) (2 arms), sponsored by Region Uppsala. Primary endpoint: Disease progression. Started Dec 2010; status: completed.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2010-023560-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023560-40.